Overview

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
To evaluate safety and efficacy of AIV001 treatment on low-risk basal cell carcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AiViva BioPharma, Inc.